| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	
 
																	Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued...
 
																	TD Cowen analyst Yaron Werber downgrades Alector (NASDAQ:ALEC) from Buy to Hold.
 
																	Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector (NASDAQ:ALEC) from Overweight to Neutral.
 
																	HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers the price target from $10 ...
 
																	
 
																	
